Hermle L, Szlak-Rubin R, Täschner K L, Peukert P, Batra A
Klinik für Psychiatrie und Psychotherapie Christophsbad, Faurndauer Str. 6-28, 73035 Göppingen, Deutschland.
Nervenarzt. 2013 Mar;84(3):315-25. doi: 10.1007/s00115-011-3459-4.
Alcohol and substance use disorders (ASUD) are considered to be among the most frequent comorbidities in schizophrenic and affective psychoses and have a significant negative influence on their course and prognosis. In the present study patients with diagnosis from the ICD-10 category F2 or F3 were examined regarding a substance use disorder in a multicentre cross-section evaluation at nine psychiatric hospitals in Baden-Württemberg. The aim of this study is to discuss the current research on substance use disorders and psychosis comorbidity regarding the theoretical models by means of collected data.
The examination of 50 consecutive admissions per centre is based on a shortened version of the European Severity Index (Europ ASI). An initial urine drug screening was carried out with all patients after admission. Statistical assessment was based on percentage distributions, mean values, standard deviations and suitable correlation analysis.
The representative sample included 448 patients. A proportion of 169 patients (37.7%) had a dual diagnosis F2 and F1 and a proportion of 144 patients (32.1%) had a dual diagnosis F3 and F1; 64 patients (14.3%) had an F2 diagnosis and 71 patients (15.8%) had an F3 diagnosis without ASUD. Apart from lifetime use of alcohol (n = 268) and tobacco (n = 325) hypnotics/tranquilizers (n = 214), cannabis (n = 156), opioids (n = 71), stimulants (n = 96) and hallucinogens (n = 36) were consumed. The most frequent combination and long-term intake consisted of tobacco, alcohol, hypnotics/tranquilizer, cannabis and psychostimulants especially in men with schizophrenic disorders. Regarding motivation before first substance use general psychological adjustment disorders (51%), peer impact (42%) and unspecific affective symptoms were predominant.
Altogether the present study clearly demonstrates that patients suffering from schizophrenia, affective disorders and ASUD have significantly higher rates of more severe substance use disorders in their psychosocial environment and more suicidal behaviour than patients without substance misuse. The high rate in the cross-sectional prevalence of tobacco, alcohol, cannabis and psychostimulant use calls for more effective drug prevention.
酒精和物质使用障碍(ASUD)被认为是精神分裂症和情感性精神病中最常见的共病之一,对其病程和预后有显著负面影响。在本研究中,对来自巴登-符腾堡州九家精神病医院的多中心横断面评估中,对国际疾病分类第10版(ICD-10)F2或F3类诊断的患者进行了物质使用障碍检查。本研究的目的是通过收集的数据,根据理论模型讨论目前关于物质使用障碍与精神病共病的研究。
每个中心连续检查50名入院患者,基于欧洲严重程度指数(Europ ASI)的简化版本。所有患者入院后进行了初步尿液药物筛查。统计评估基于百分比分布、平均值、标准差和适当的相关性分析。
代表性样本包括448名患者。169名患者(37.7%)有F2和F1双重诊断,144名患者(32.1%)有F3和F1双重诊断;64名患者(14.3%)有F2诊断,71名患者(15.8%)有F3诊断但无ASUD。除了终生饮酒(n = 268)和吸烟(n = 325)外,还使用了催眠药/镇静剂(n = 214)、大麻(n = 156)、阿片类药物(n = 71)、兴奋剂(n = 96)和致幻剂(n = 36)。最常见的组合和长期摄入包括烟草、酒精、催眠药/镇静剂、大麻和精神兴奋剂,尤其是在患有精神分裂症的男性中。关于首次使用物质之前的动机,一般心理适应障碍(51%)、同伴影响(42%)和非特异性情感症状占主导地位。
总体而言,本研究清楚地表明,与没有物质滥用的患者相比,患有精神分裂症、情感障碍和ASUD的患者在其心理社会环境中更严重的物质使用障碍和自杀行为的发生率显著更高。烟草、酒精、大麻和精神兴奋剂使用的横断面患病率很高,需要更有效的药物预防。